Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå : µî±Þº°, ¿ëµµº°, °³¹ß ´Ü°èº°, Áúȯº°, ±¹°¡º°, Áö¿ªº° - »ê¾÷ ºÐ¼®, ½ÃÀå ±Ô¸ð, ½ÃÀå Á¡À¯À², ¿¹Ãø(2024-2032³â)
Plasmid DNA Manufacturing Market, By Grade, By Application, By Development Phase, By Disease, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
»óǰÄÚµå : 1485794
¸®¼­Ä¡»ç : AnalystView Market Insights
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 399 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,250 £Ü 4,459,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç, ÅØ½ºÆ®ÀÇ Copy&Pasteµµ ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 4,650 £Ü 6,380,000
PDF (5 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,650 £Ü 7,752,000
PDF & Excel (Enterprise User License) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ³» ¸ðµç »ç¿ëÀÚ°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy&Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸®Æ÷Æ® ÇÏÀ̶óÀÌÆ®

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 17¾ï 8,898¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â CAGR 21.5%·Î È®´ë

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ½ÃÀå ¿ªÇÐ

¿¬±¸°³¹ß Ȱµ¿ÀÇ È°¹ßÈ­, À¯Àü¼º Áúȯ ¹× °¨¿°ÁõÀÇ À¯ÇàÀÇ Áõ°¡°¡ ½ÃÀå ¼ö¿ä¸¦ ÃËÁø

¿¬±¸°³¹ß Ȱµ¿ Áõ°¡, ¹ÙÀÌ¿À ÀǾàǰ¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, À¯ÀüÀÚ ÀÌ»ó ¹× °¨¿°¼º ÁúȯÀÇ ºóµµ Áõ°¡ µî ´Ù¾çÇÑ ÀÌÀ¯°¡ Çö󽺹̵å DNA Á¦Á¶ ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ Á¤¹ÐÀÇ·áÀÇ ¹ßÀü°ú »õ·Î¿î ¸é¿ªÄ¡·áÁ¦ÀÇ °³¹ßÀº Çö󽺹̵å DNA ±â¹Ý ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ¹ßÀü°ú ½ÂÀÎ ÀýÂ÷ÀÇ ´ÜÃàÀº ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ°í ¿¬±¸ ¹ß°ßÀ» º¸´Ù ½Å¼ÓÇÏ°Ô ÀÓ»ó Àû¿ëÀ¸·Î ÀüȯÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ÁÖ¿ä ÀλçÀÌÆ®

AnalystView Market InsightsÀÇ ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®µéÀÇ ºÐ¼®¿¡ µû¸£¸é ¼¼°è ½ÃÀåÀº ¿¹Ãø ±â°£(2024-2032) µ¿¾È ¿¬Æò±Õ ¾à 21.5%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­¿¡ µû¸£¸é 2023³â¿¡´Â R&D µî±ÞÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿ëµµº°·Î´Â DNA ¹é½ÅÀÌ 2023³â ÁÖ¿ä À¯ÇüÀ¸·Î ºÎ»óÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

°³¹ß ´Ü°èº°·Î´Â 2023³â¿¡´Â ÀüÀÓ»ó Ä¡·áÁ¦°¡ ÁÖ¿ä À¯ÇüÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Áö¿ªº°·Î´Â ºÏ¹Ì°¡ 2023³â ¸ÅÃâ 1À§

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ¼¼ºÐÈ­ ºÐ¼® :

¼¼°è Çö󽺹̵å DNA Á¦Á¶ ½ÃÀåÀº µî±Þ, ¿ëµµ, °³¹ß ´Ü°è, Áúº´ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½ÃÀåÀº µî±Þº°·Î R&D µî±Þ, GMP µî±Þ, R&D µî±Þ ºÐ¾ß°¡ ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¿¬±¸°³¹ß Ãʱ⠴ܰ迡¼­ ³Î¸® »ç¿ëµÇ´Â R&D µî±Þ Çö󽺹̵å DNA´Â °úÇÐÀÚµéÀÌ »õ·Î¿î Ä¡·á °³³äÀ» ޱ¸Çϰí ÀüÀÓ»ó È¿´ÉÀ» °ËÁõÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù.

½ÃÀåÀº ¿ëµµ¿¡ µû¶ó DNA ¹é½Å, ¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á, ¸é¿ª Ä¡·á, ±âŸ·Î ³ª´µ¸ç, DNA ¹é½Å ºÐ¾ß´Â ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ Áß¿¡µµ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º´¿øÃ¼¸¦ ÀνÄÇÏ°í ½Î¿ì´Â ¸é¿ªÃ¼°èÀÇ ´É·ÂÀ» Ȱ¿ëÇÏ´Â DNA ¹é½ÅÀº °¨¿°º´À» ¿¹¹æÇÏ°í »õ·Î¿î °Ç°­ À§Çù¿¡ ´ëóÇÒ ¼ö ÀÖ´Â À¯¸ÁÇÑ Á¢±Ù¹ýÀ» Á¦°øÇÕ´Ï´Ù.

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - Áö¿ªÀû ÀλçÀÌÆ®

Áö¿ªÀûÀ¸·Î ÀÌ ½ÃÀåÀº ºÏ¹Ì, ¶óƾ¾Æ¸Þ¸®Ä«, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«À¸·Î ³ª´¹´Ï´Ù. ÀÌ Áö¿ªÀº ºñÁî´Ï½º¸¦ °¡Á® ¿À´Â ±¹°¡¿¡ µû¶ó ´õ ¼¼ºÐÈ­µË´Ï´Ù.

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - °æÀï»óȲ :

Çö󽺹̵å DNA Á¦Á¶ ½ÃÀåÀº °æÀïÀÌ Ä¡¿­Çϸç, À¯¸íÇÑ °æÀï¾÷üµéÀÌ »õ·Î¿î Á¦Á¶ °øÁ¤°ú È®Àå °¡´ÉÇÑ »ý»ê ´É·ÂÀ¸·Î ÆÐ±ÇÀ» ´ÙÅõ°í ÀÖ½À´Ï´Ù. °¢ ¾÷üµéÀº Àü·«Àû Á¦ÈÞ, Àμö, R&D ºñ¿ëÀ» ÅëÇØ ½ÃÀå ÁöÀ§¸¦ °­È­Çϰí Á¦Ç° ¶óÀξ÷À» È®´ëÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ±â¾÷Àº À¯ÀüÀÚ Ä¡·á, ¹é½Å ¿¬±¸, ¹ÙÀÌ¿À ÀǾàǰ Á¦Á¶ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Áõ°¡ÇÏ´Â Çö󽺹̵å DNA ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ Ç°Áú º¸Áõ, ±ÔÁ¦ Áؼö, ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼ÇÀ» ¿ì¼±¼øÀ§¿¡ µÎ°í ÀÖ½À´Ï´Ù. °æÀï ¿ìÀ§¸¦ À¯ÁöÇϱâ À§ÇØ ±â¾÷Àº ²÷ÀÓ¾øÀÌ º¯È­ÇÏ´Â ½ÃÀå µ¿Çâ°ú °í°´ ¼ö¿ä¿¡ ÀûÀÀÇØ¾ß ÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå °³¿ä

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Çö󽺹̵å DNA Á¦Á¶ÀÇ ÁÖ¿ä ½ÃÀå µ¿Çâ

Á¦4Àå Çö󽺹̵å DNA Á¦Á¶ »ê¾÷ ¿¬±¸

Á¦5Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå : COVID-19ÀÇ ¿µÇ⠺м®

Á¦6Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå ±¸µµ

Á¦7Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - µî±Þº°

Á¦8Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - °³¹ß ´Ü°èº°

Á¦9Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - ¿ëµµº°

Á¦10Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - Áúȯº°

Á¦11Àå Çö󽺹̵å DNA Á¦Á¶ ½ÃÀå - Áö¿ªº°

Á¦12Àå ÁÖ¿ä º¥´õ ºÐ¼® - Çö󽺹̵å DNA Á¦Á¶¾÷°è

Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ Àü¹æÀ§ Àü¸Á

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

REPORT HIGHLIGHT

Plasmid DNA Manufacturing Market size was valued at USD 1,788.98 Million in 2023, expanding at a CAGR of 21.5% from 2024 to 2032.

The Global Plasmid DNA Manufacturing Market is seeing substantial expansion and transition, owing to advances in biopharmaceutical study and development. Plasmid DNA, a flexible molecular tool, serves as the basis for a wide range of therapeutic applications, including DNA vaccinations, cell and gene therapy. As the need for personalised medicine and targeted therapies continues to develop, the market for plasmid DNA synthesis is positioned to significantly expand.

Plasmid DNA Manufacturing Market- Market Dynamics

Increasing research and development activities and the rising prevalence of genetic disorders and infectious diseases propel market demand

A variety of reasons are driving the Plasmid DNA Manufacturing marketplace, including increased R&D efforts, increased biopharmaceutical investments, and the rising frequency of genetic abnormalities and infectious illnesses. Furthermore, the move towards precision medicine and the development of new immunotherapies are driving up demand for plasmid DNA-based medicines. Regulatory advances and shortened approval procedures boost market expansion, allowing speedier translation of research discoveries into clinical applications.

Plasmid DNA Manufacturing Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 21.5% over the forecast period (2024-2032)

Based on Grade segmentation, R&D Grade was predicted to show maximum market share in the year 2023

Based on application segmentation, DNA Vaccines was the leading type in 2023

Based on Development Phase segmentation, Pre-Clinical Therapeutics was the leading type in 2023

Based on region, North America was the leading revenue generator in 2023

Plasmid DNA Manufacturing Market- Segmentation Analysis:

The Global Plasmid DNA Manufacturing Market is segmented based on Grade, Application, Development Phase, Disease, and Region.

The market is divided into three categories based on Grade: R&D Grade, GMP Grade. The R&D Grade sector dominates the market. Widely used in early-stage research and development, R&D Grade plasmid DNA enables scientists to explore novel therapeutic concepts and validate preclinical efficacy.

The market is divided into two categories based on application: DNA Vaccines, Cell & Gene Therapy, Immunotherapy, and Others. The DNA vaccine segment dominates the market and is likely to maintain its dominance during the forecast period. Leveraging the immune system's ability to recognize and combat pathogens, DNA vaccines offer a promising approach to preventing infectious diseases and addressing emerging health threats.

Plasmid DNA Manufacturing Market- Geographical Insights

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Plasmid DNA Manufacturing Market- Competitive Landscape:

The Plasmid DNA Manufacturing Market is competitive, with prominent competitors vying for supremacy via novel manufacturing processes and scalable production capacity. Companies use strategic alliances, acquisitions, and R&D expenditures to strengthen their market position and broaden their product offerings. Leading companies prioritise quality assurance, regulatory compliance, and cost-effective solutions to fulfil the expanding demand for plasmid DNA in a variety of applications, including gene therapy, vaccine research, and biopharmaceutical manufacturing. To sustain their competitive advantage, businesses must constantly adapt to changing market trends and client demands.

Recent Developments:

In February 2023, PackGene Biotech expanded its services with the opening of an innovative GMP biomanufacturing and processing plant in Houston, Texas. This comprises gene therapy programmes that produce cost-effective, dependable, and scalable AAV products. With this development, the business hopes to become a one-stop solution supplier for gene therapy developers.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL PLASMID DNA MANUFACTURING MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Nature Technology

Cell and Gene Therapy Catapult

Danaher (Aldevron)

Kaneka Corp.

Eurofins Genomics

Lonza

Charles River Laboratories

VGXI, Inc.

Luminous BioSciences, LLC

Akron Biotech

Others

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY GRADE- MARKET ANALYSIS, 2019 - 2032

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DEVELOPMENT PHASE- MARKET ANALYSIS, 2019 - 2032

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY DISEASE- MARKET ANALYSIS, 2019 - 2032

GLOBAL PLASMID DNA MANUFACTURING MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

Table of Contents

1.Plasmid DNA Manufacturing Market Overview

2.Executive Summary

3.Plasmid DNA Manufacturing Key Market Trends

4.Plasmid DNA Manufacturing Industry Study

5.Plasmid DNA Manufacturing Market: COVID-19 Impact Analysis

6.Plasmid DNA Manufacturing Market Landscape

7.Plasmid DNA Manufacturing Market - By Grade

8.Plasmid DNA Manufacturing Market - By Development Phase

9.Plasmid DNA Manufacturing Market - By Application

10.Plasmid DNA Manufacturing Market - By Disease

11.Plasmid DNA Manufacturing Market- By Geography

12.Key Vendor Analysis- Plasmid DNA Manufacturing Industry

13.360 Degree Analyst View

14.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â